during a recent interview with HCPLive:Dr. Glynis Ablon answered a series of questions regarding his recent presentation at the 2023 Winter Clinical Dermatology Conference, titled “New Devices for Your Practice.”
Ablon is the founder of the Ablon Skin Institute & Research Center and also serves as an associate clinical professor at UCLA.
He first explored some of the key talking points outlined in his presentation, highlighting what physicians should consider before adopting new devices into their practice.
“Technology seems to be advancing at the speed of light.”
“It’s always exciting to evaluate new devices at the forefront of aesthetic dermatology,” he explained. “In my lecture, I like to remind other doctors that it’s important to do your due diligence before purchasing new devices. I break it down into three sections: calculating your risk, deciding what equipment you need, and finances. When you’re actually ready to introduce another device into your practice, it’s always important to know what’s out there and what’s new.”
Ablon explained a little more about the devices studied in his presentation, listing their companies and noting their uses and designs.
“I plan to quickly touch on six new devices, including the newest, fractional, cold ablative fiber laser from Acclaro called UltraClear,” he said, adding that he used “the only FDA-approved, low-level laser to cure the device.” excess fat and obesity, from Erchonia, called Emerald, (and) synchronous parallel ultrasound technology, now FDA-approved for cellulite from Sofwave.”
He explained the use of “EndyMed’s fractional, radiofrequency, microneedling devices” as well as “Sentis’ thermomechanical, fractional, fractional alloy tip for skin tightening to tighten the skin, especially periorbital and folds.”
Another device he explained aimed at clinicians was Sensus’ TransDermal Infusion device, which provided needle-free delivery using microelectric currents.
“In dermatology, it’s always important to find devices that take less time, less discomfort, but equal effectiveness. And that’s what all these devices do.”
Ablon also explained why dermatologists might want to understand how these types of tools work.
“With so many new devices out there, it’s important to understand how the technologies work, what they actually do what they say they do, and how different they are than what came before,” he said. “I always explain that it is important to test these devices in your own practice and see that you can get the results you expect with little or no downtime and little worry to make them effective in your practice.”
Ablon added that he believes many of the new devices on the market have unique features, and if they don’t, they won’t be successful for clinicians.
In the final part of his interview, Ablon explained his views on telling companies about the use of their devices and whether or not he is optimistic about the future of these tools.
“I’m a straight shooter,” he said. “I speak about what I believe. If I try something and I really don’t like it, or it doesn’t do what the company says, I’ll tell them, “Good day. But if I’m excited about the results I see when I use a new device in my practice, I’ll talk about it and share it with my colleagues.”
Comments